

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Carton}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Librela 20 mg Solution for injection

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Each 1 ml contains 20 mg bedinvetmab.

**3. PACKAGE SIZE**

1 x 1 ml

2 x 1 ml

6 x 1 ml

**4. TARGET SPECIES**

Dogs

**5. INDICATION(S)**

**6. ROUTES OF ADMINISTRATION**

Subcutaneous use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.

Do not freeze.

Store in the original package.

Protect from light.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

**14. MARKETING AUTHORISATION NUMBER**

Vm 42058/5032

**15. BATCH NUMBER**

Lot {number}

**16. SPECIAL WARNING(S), IF NECESSARY**

**17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE**

**POM-V**

To be supplied only on veterinary prescription.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING**  
**UNITS {Vial label}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Librela



**2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCE(S)**

bedinvetmab 20 mg/ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

**5. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

**6. ROUTE(S) OF ADMINISTRATION**

SC

**7. WITHDRAWAL PERIOD**

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Librela 20 mg solution for injection for dogs

### **2. COMPOSITION**

#### **Active substance:**

Each vial of 1 ml contains 5 mg, 10 mg, 15 mg, 20 mg or 30 mg bedinvetmab\*.

\* Bedinvetmab is a canine monoclonal antibody expressed through recombinant techniques in Chinese hamster ovary (CHO) cells.

The product should appear clear to slightly opalescent without any visible particles.

### **3. TARGET SPECIES**

Dogs.

### **4. INDICATIONS FOR USE**

For the alleviation of pain associated with osteoarthritis in dogs.

### **5. CONTRAINDICATIONS**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs under 12 months.

Do not use in animals intended for breeding.

Do not use in pregnant or lactating animals.

### **6. SPECIAL WARNING(S)**

#### **Special warnings:**

This veterinary medicinal product may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect or may result in a decrease in efficacy in animals that responded to treatment previously.

If no or limited response is observed within one month after initial dosing, an improvement in response may be observed after administration of a second dose one month later. However, if the animal does not show a better response after the second dose, the veterinary surgeon should consider alternative treatments.

Special precautions for safe use in the target species:

Where a dog has not been able to properly exercise prior to treatment due to its clinical condition, it is recommended that the dog is gradually (over a few weeks) allowed to increase the amount of exercise they take (to prevent overexercise by some dogs).

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection. Repeated self-administration may increase the risk of hypersensitivity reactions.

The importance of nerve growth factor (NGF) in ensuring normal foetal nervous system development is well-established and laboratory studies conducted on non-human primates with human anti-NGF antibodies have shown evidence of reproductive and developmental toxicity. Pregnant women, women trying to conceive and breastfeeding women should take extreme care to avoid accidental self-injection.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in breeding dogs. Laboratory studies with human anti-NGF antibodies in cynomolgus monkeys have shown evidence of teratogenic and foetotoxic effects.

Do not use in pregnant or lactating animals.

Fertility:

Do not use in breeding animals.

Interaction with other medicinal products and other forms of interaction:

In a laboratory study over a 2-week period in young, healthy dogs without osteoarthritis, this veterinary medicinal product had no adverse effect when concomitantly administered with a non-steroidal anti-inflammatory product (carprofen).

There are no safety data on the concurrent long-term use of NSAIDs and bedinvetmab in dogs. In clinical trials in humans, rapidly progressive osteoarthritis has been reported in patients receiving humanised anti-NGF monoclonal antibody therapy. The incidence of these events increased with high doses and in those human patients that received long-term (more than 90 days) non-steroidal anti-inflammatory drugs (NSAIDs) concomitantly with an anti-NGF monoclonal antibody. Dogs have no reported equivalent of human rapidly progressive osteoarthritis.

No other laboratory studies on the safety of concomitant administration of this veterinary medicinal product with other veterinary medicinal products have been conducted. No interactions were observed in field studies where this veterinary medicinal product was administered concomitantly with veterinary medicinal products containing parasiticides, antimicrobials, topical antiseptics with or without corticosteroids, antihistamines and vaccines.

If a vaccine(s) is to be administered at the same time as treatment with this veterinary medicinal product, the vaccine(s) should be administered at a different site to that of Librela's administration, to reduce any potential impact on immunogenicity of the vaccine.

Overdose:

No adverse reactions, except mild reactions at the injection site, were observed in a laboratory overdose study when Librela was administered for 7 consecutive monthly doses at 10 times the maximum recommended dose.

In case of adverse clinical signs after an overdose the dog should be treated symptomatically.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

**7. ADVERSE EVENTS**

Dogs:

Uncommon (1 to 10 animals / 1,000 animals treated):	Injection site reaction (injection site swelling, injection site warmth) <sup>1</sup> .
Rare (1 to 10 animals / 10,000 animals treated):	Increased thirst (polydipsia). Increased need to urinate (polyuria).
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction (anaphylaxis, facial swelling, itching (pruritus)) <sup>2</sup> , low amounts of red blood cells and thrombocytes (immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia).

<sup>1</sup> Mild

<sup>2</sup> In case of such reactions, appropriate symptomatic treatment should be administered.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system.

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Subcutaneous use.

### Dosage and treatment schedule:

The recommended dose is 0.5-1.0 mg/kg bodyweight, once a month.

Dogs weighing <5.0 kg:  
Aseptically withdraw 0.1 ml/kg from a single 5 mg/ml vial and administer subcutaneously.

For dogs between 5 and 60 kg administer the entire content of the vial (1 ml) according to the table below:

Bodyweight (kg) of dog	LIBRELA strength (mg) to be administered				
	5	10	15	20	30
<b>5.0-10.0</b>	<b>1 vial</b>				
<b>10.1-20.0</b>		<b>1 vial</b>			
<b>20.1-30.0</b>			<b>1 vial</b>		
<b>30.1-40.0</b>				<b>1 vial</b>	
<b>40.1-60.0</b>					<b>1 vial</b>
<b>60.1-80.0</b>				<b>2 vials</b>	
<b>80.1-100.0</b>				<b>1 vial</b>	<b>1 vial</b>
<b>100.1-120.00</b>					<b>2 vials</b>

For dogs above 60 kg, the contents of more than one vial are required to administer a single dose. In those cases, withdraw the content from each required vial into the same syringe and administer as a single subcutaneous injection (2 ml).

## 9. ADVICE ON CORRECT ADMINISTRATION

None.

## 10. WITHDRAWAL PERIOD(S)

Not applicable.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Store in the original package.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: use immediately.

## **12. SPECIAL PRECAUTIONS FOR DISPOSAL**

Medicines should not be disposed of via wastewater.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

## **13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 42058/5032

Clear glass Type I vials with fluorobutyl rubber stopper.

Pack sizes:

Cardboard box with 1, 2 or 6 vials of 1 ml

Not all pack sizes may be marketed.

## **15. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST REVISED**

September 2023

Find more product information by searching for the 'Product Information Database' or 'PID' on [www.gov.uk](http://www.gov.uk)

## **16. CONTACT DETAILS**

Marketing authorisation holder and manufacturer responsible for batch release:

Zoetis Belgium  
Rue Laid Burniat 1  
1348 Louvain-La-Neuve  
Belgium



Local representatives and contact details to report suspected adverse reactions:

**België/Belgique/Belgien**

Zoetis Belgium  
Mercuriusstraat 20  
BE-1930 Zaventem  
Tél/Tel: +32 (0) 800 99 189

**Република България**

Zoetis Belgium  
Rue Laid Burniat 1  
1348 Louvain-La-Neuve  
Белгия  
Тел: +359 888 51 30 30

**Česká republika**

Zoetis Česká republika, s.r.o.  
náměstí 14. října 642/17  
CZ 150 00 Praha  
Tel: +420 257 101 111

**Danmark**

Zoetis Animal Health ApS  
Øster Alle 48  
DK-2100 København  
Tlf: +45 70 20 73 05  
adr.scandinavia@zoetis.com

**Deutschland**

Zoetis Deutschland GmbH  
Schellingstr. 1  
DE-10785 Berlin  
Tel: +49 30 2020 0049  
[tierarzneimittelsicherheit@zoetis.com](mailto:tierarzneimittelsicherheit@zoetis.com)

**Eesti**

Zoetis Belgium  
Mercuriusstraat 20  
1930 Zaventem  
Belgia  
Tel: +370 610 05088

**Ελλάδα**

Zoetis Hellas S.A.  
Φραγκοκκλησιάς 7, Μαρούσι  
EL-15125 Αττική  
Τηλ: +30 210 6791900

**Lietuva**

Zoetis Belgium  
Mercuriusstraat 20  
1930 Zaventem  
Belgija  
Tel: +370 610 05088

**Luxembourg/Luxemburg**

Zoetis Belgium  
Mercuriusstraat 20  
1930 Zaventem  
Belsch  
Tél/Tel: +32 (2) 746 80 11

**Magyarország**

Zoetis Hungary Kft.  
Csörsz u. 41.  
HU-1124 Budapest  
Tel.: +36 1 224 5200

**Malta**

Agrimed Limited  
Mdina Road, Zebbug ZBG 9016,  
MT  
Tel: +356 21 465 797

**Nederland**

Zoetis B.V.  
Rivium Westlaan 74  
NL-2909 LD Capelle aan den IJssel  
Tel: +31 (0)10 714 0900

**Norge**

Zoetis Animal Health ApS  
Øster Alle 48  
DK-2100 København  
Danmark  
Tlf: +47 23 29 86 80  
adr.scandinavia@zoetis.com

**Österreich**

Zoetis Österreich GmbH  
Floridsdorfer Hauptstr. 1  
AT-1210 Wien  
Tel: +43 (0)1 2701100 100

### **España**

Zoetis Spain, S.L.  
Parque Empresarial Vía Norte Edificio  
nº1,  
c/ Quintanavides nº13  
ES-28050 Madrid  
Tel: +34 91 4191900

### **France**

Zoetis France  
10 rue Raymond David  
FR-92240 Malakoff  
Tél: +33 (0)800 73 00 65

### **Hrvatska**

Zoetis B.V.  
Podružnica Zagreb za promidžbu  
Petra Hektorovića 2  
HR-10000 Zagreb  
Tel: +385 1 6441 462

### **Ireland**

Zoetis Belgium S.A. (Irish Branch)  
2nd Floor, Building 10,  
Cherrywood Business Park,  
Loughlinstown,  
Co. Dublin,  
IE – Dublin D18 T3Y1  
Tel: +353 (0) 1 256 9800

### **Ísland**

Zoetis Animal Health ApS  
Øster Alle 48  
DK-2100 København  
Danmörku  
Sími: +45 70 20 73 05  
adr.scandinavia@zoetis.com

### **Italia**

Zoetis Italia S.r.l.  
Via Andrea Doria 41M,  
IT-00192 Roma  
Tel: +39 06 3366 8111

### **Polska**

Zoetis Polska Sp. z o.o.  
ul. Postępu 17B  
PL - 02-676 Warszawa  
Tel.: +48 22 2234800

### **Portugal**

Zoetis Portugal Lda.  
Lagoas Park, Edifício 10  
PT-2740-271 Porto Salvo  
Tel: +351 21 042 72 00

### **România**

Zoetis România S.R.L.  
Expo Business Park, 54A Aviator  
Popișteanu, Clădirea 2, Etaj 1-3, Sector  
1,  
București, 012095 - RO  
Tel: +40785019479

### **Slovenija**

Zoetis B.V.  
Podružnica Zagreb za promidžbu  
Petra Hektorovića 2,  
10000 Zagreb,  
Hrvaška  
Tel: +385 1 6441 462

### **Slovenská republika**

Zoetis Česká republika, s.r.o.  
náměstí 14. října 642/17  
150 00 Praha  
Česká republika  
Tel: +420 257 101 111

### **Suomi/Finland**

Zoetis Finland Oy  
Bulevardi 21 / SPACES  
FI-00180 Helsinki/Helsingfors  
Suomi/Finland  
Puh/Tel: +358 10 336 7000  
laaketurva@zoetis.com

**Κύπρος**

Zoetis Hellas S.A.  
Φραγκοκκλησιάς 7, Μαρούσι  
15125, ΑΤΤΙΚή  
Ελλάδα  
Τηλ: +30 210 6791900

**Sverige**

Zoetis Animal Health ApS  
Øster Alle 48  
DK-2100 Köpenhamn  
Danmark  
Tel: +46 (0) 76 760 0677  
adr.scandinavia@zoetis.com

**Latvija**

Zoetis Belgium  
Mercuriusstraat 20  
1930 Zaventem  
Βελγία  
Tel: +370 610 05088


**United Kingdom (Northern Ireland)**

Zoetis Belgium S.A. (Irish Branch)  
2nd Floor, Building 10,  
Cherrywood Business Park,  
Loughlinstown,  
Co. Dublin,  
IE – Dublin D18 T3Y1  
Tel: +353 (0) 1 256 9800

**United Kingdom (Great Britain)**

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey, KT22 7LP  
UK  
Tel: +44 (0) 345 300 8034

**17. OTHER INFORMATION**



Approved: 19 September 2023